BIOA
BioAge Labs, Inc.
There isn't enough reported data to score BIOA yet.
BIOA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
BIOA's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
BIOA PE Valuation
BIOA has no meaningful PE right now: it lost money over the past year.
BIOA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect BIOA's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
BIOA Earnings Per Share
BIOA lost $2.55 per share over the past year, a bigger loss than the year before.
BIOA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $298K | -85% |
| Q2 2026 | $2.5M | +1.6% |
| Q1 2026 | $2.8M | +91% |
BIOA's revenue is growing: $298,000 last quarter, down 85% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12554% | -11428 points |
| Q2 2026 | -1197% | -170 points |
| Q1 2026 | -915% | +218 points |
| Q4 2025 | -923% | N/A |
| Q3 2025 | -1127% | N/A |
| Q2 2025 | -1027% | N/A |
| Q1 2025 | -1133% | N/A |
BIOA's operating margin was −12554% last quarter, down 11427 points from the same quarter a year ago, near the bottom of its range since 2025.
BIOA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$31M | -$14.9M |
| Q2 2026 | -$19.6M | +$540K |
| Q1 2026 | -$24.1M | -$6.3M |
| Q4 2025 | -$28.4M | -$23.2M |
| Q2 2025 | -$20.1M | -$4.3M |
| Q1 2025 | -$17.8M | -$2.1M |
| Q4 2024 | -$5.2M | +$3.3M |
| Q2 2024 | -$15.8M | -$4.7M |
BIOA has burned cash in almost every quarter: −$103M over the past year, against −$59M the year before.
BIOA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +1.1M shares |
| 1 year | +28% | +10.1M shares |
| 3 years | +34% | +11.7M shares |
BIOA has 46M diluted shares, up 28% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
BIOA Net Leverage
BIOA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BIOA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 8.2 | Oversold |
BIOA's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
BIOA PE vs Healthcare Sector
BIOA has no meaningful PE right now: it lost money over the past year.
BIOA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.85 | 3.4% below |
| 20 week MA | $10.9 | 48% below |
| 50 week MA | $14.9 | 62% below |
| 100 week MA | $9.96 | 43% below |
BIOA is in a downtrend: it's below all four of its weekly moving averages, and 43% below its 100-week average.
BIOA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $21.0 | $5.50 | -74% |
| 2025 | $5.50 | $13.9 | +152% |
| 2026 YTD | $13.9 | $5.65 | -59% |
BIOA's yearly returns have swung widely, from +152% in 2025 to −74% in 2024. It's down 59% so far in 2026.